Fierce Pharma’s initial field of 32 is down to the Sweet 16.
Eli Lilly’s diabetes med Mounjaro strolled to victory over Bristol Myers Squibb’s heart drug Camzyos by 72% to 28%.
Novartis’ prostate cancer therapy Pluvicto also cruised to an easy victory over Chiesi’s alpha-mannosidosis treatment Lamzede.
Click here to view the other winners.